149 related articles for article (PubMed ID: 15041119)
1. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
Dumon JC; Journé F; Kheddoumi N; Lagneaux L; Body JJ
Eur Urol; 2004 Apr; 45(4):521-8; discussion 528-9. PubMed ID: 15041119
[TBL] [Abstract][Full Text] [Related]
2. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate treatment inhibits the growth of prostate cancer cells.
Lee MV; Fong EM; Singer FR; Guenette RS
Cancer Res; 2001 Mar; 61(6):2602-8. PubMed ID: 11289137
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
5. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines.
Pandha H; Birchall L; Meyer B; Wilson N; Relph K; Anderson C; Harrington K
J Urol; 2006 Nov; 176(5):2255-61. PubMed ID: 17070308
[TBL] [Abstract][Full Text] [Related]
8. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
Tanaka T; Kawashima H; Ohnishi K; Matsumura K; Yoshimura R; Matsuyama M; Kuratsukuri K; Nakatani T
Anticancer Res; 2009 Apr; 29(4):1089-94. PubMed ID: 19414350
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates for the prevention of bone metastases.
Coleman RE
Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Corey E; Brown LG; Quinn JE; Poot M; Roudier MP; Higano CS; Vessella RL
Clin Cancer Res; 2003 Jan; 9(1):295-306. PubMed ID: 12538482
[TBL] [Abstract][Full Text] [Related]
14. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
15. Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells.
Tenta R; Tiblalexi D; Sotiriou E; Lembessis P; Manoussakis M; Koutsilieris M
Prostate; 2004 May; 59(2):120-31. PubMed ID: 15042612
[TBL] [Abstract][Full Text] [Related]
16. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
[TBL] [Abstract][Full Text] [Related]
17. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation.
Coxon JP; Oades GM; Kirby RS; Colston KW
BJU Int; 2004 Jul; 94(1):164-70. PubMed ID: 15217454
[TBL] [Abstract][Full Text] [Related]
19. Toward new horizons: the future of bisphosphonate therapy.
Lipton A
Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
[TBL] [Abstract][Full Text] [Related]
20. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]